Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Genentech Rituxan Failed Lupus Trial Also Takes Down Ocrelizumab For SLE

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Genentech is abandoning development of both its anti-CD20 monoclonal antibodies for systemic lupus erythematosus after the failure of Rituxan (rituximab) in the Phase II/III EXPLORER trial cast doubt on the validity of targeting the CD20 antigen on B-cells as an approach to SLE.

You may also be interested in...

Dropping Ocrelizumab Could Be Good For Biogen Idec's Cash Flow

The motion-picture-industry themed ocrelizumab RA program won't be taking home any awards with the FILM study on clinical hold and the SCRIPT trial halted after deaths from infection.

Biogen-Idec Prevails Over Genentech In Arbitration For Control Of Rituximab

Arbitrator rules that 2003 merger combining Biogen and Idec does not forfeit company’s rituximab rights via a change-of-control.

New Business Models Needed For Drug Diagnostic Partnerships

The industry is stymied by outmoded partnership models that don’t adequately value the knowledge of diagnostic makers.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts